Drug Type Small molecule drug |
Synonyms PF 6263276, PF-06263276 |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC31H31FN8O2 |
InChIKeyXDJGNPSZQSWJCV-UHFFFAOYSA-N |
CAS Registry1421502-62-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plaque psoriasis | Phase 1 | DE | 01 Sep 2014 | |
Psoriasis vulgaris | Phase 1 | DE | 01 Sep 2014 |
Phase 1 | 15 | (PF-06263276 4% Solution) | iboisearwt(juuruekcum) = cveelhxkpe vvjzlbsgtf (fwakpoycte, hunhbitpvi - tfadnpynos) View more | - | 09 Jun 2016 | ||
(PF-06263276 Vehicle) | iboisearwt(juuruekcum) = ydknddsacf vvjzlbsgtf (fwakpoycte, udxvxxbouh - hbbsltdift) View more |